Log In
Print
BCIQ
Print
Print this Print this
 

Zelapar, selegiline

  Manage Alerts
Collapse Summary General Information
Company Valeant Pharmaceuticals International Inc.
DescriptionMonoamine oxidase B (MAO-B) inhibitor
Molecular Target Monoamine oxidase B (MAO-B)
Mechanism of ActionMonoamine oxidase B (MAO-B) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationParkinson's disease (PD)
Indication DetailsAdjunct to levodopa/carbidopa therapy in patients who show deteriorated response to existing therapy; Treat Parkinson's disease (PD)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$5,700.0M

$5,700.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today